NLRP3 and breast cancer: Thus, our current study demonstrated that NLRP3 might be an oncogene or at least possess oncogenic activity in BC and that the inhibition of NLRP3 expression by cryptotanshinone might be one of the mechanisms explaining the antitumor activity of cryptotanshinone in BC.